Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Study of Bimekizumab in Active Psoriatic Arthritis
NCT04009499Phase 3Completed
- Sponsor
- UCB
- Start
- Aug 2019
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of bimekizumab in psoriatic arthritis (PsA), sponsored by UCB. Started Aug 2019; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04009499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04009499.